



April 25, 2025
JCR Pharmaceuticals Co., Ltd.

Notice of Election of Candidate for New Audit & Supervisory Board Members

Hyogo, Japan – April 25, 2025 – [JCR Pharmaceuticals Co., Ltd.](https://www.jcr-pharm.co.jp/) (TSE 4552; “JCR”) announced today that its Board of Directors resolved at a meeting held today to nominate the following candidates for new audit & supervisory board members, to be proposed for election at the Ordinary General Meeting of Shareholders scheduled to be held on June 25, 2025. Appointments will be subject to approval at the Ordinary General Meeting of Shareholders.

1. Candidates for New Audit & Supervisory Board Members

Name	New Title	Current Title
Masayuki Mitsuka	Outside Audit & Supervisory Board Member	-
Miya Miyama	Outside Audit & Supervisory Board Member	-

2. Audit & Supervisory Board Members scheduled to retire

Name	New Title	Current Title
Kazuhiko Yamada ^{*1}	-	Outside Audit & Supervisory Board Member
Kenjiro Miyatake ^{*1}	-	Outside Audit & Supervisory Board Member
Takeshi Komura ^{*2}	-	Outside Audit & Supervisory Board Member
Shuichi Tani ^{*2}	-	Outside Audit & Supervisory Board Member

^{*1}. For personal reasons, they will resign as audit & supervisory board members at the conclusion of the Ordinary General Meeting of Shareholders scheduled to be held on June 25, 2025, before the expiration of their terms of office.

^{*2}. The terms of office will expire at the conclusion of the Ordinary General Meeting of Shareholders scheduled to be held on June 25, 2025, and they will retire from the positions of audit & supervisory board members.

3. Brief personal histories of candidates for new audit & supervisory board member

[Name]	Masayuki Mitsuka
[Date of Birth]	October 30, 1954
[Brief biography]	
April 1982	Joined Mitsubishi Chemical Industries (currently Mitsubishi Chemical Corporation)
June 2009	Board Director, Executive Officer, and General Manager of Global Product Strategy Department of Mitsubishi Tanabe Pharma Corporation
April 2012	Board Director, Managing Executive Officer, and Division Manager of Development Division of Mitsubishi Tanabe Pharma Corporation
April 2014	Representative Director and Senior Managing Executive Officer of Mitsubishi Tanabe Pharma Corporation
June 2014	President & Representative Director and Chief Executive Officer of Mitsubishi Tanabe Pharma Corporation
April 2020	Board Director of Mitsubishi Tanabe Pharma Corporation
June 2020	Advisor of Mitsubishi Tanabe Pharma Corporation
July 2022	Advisor of MEDIPAL HOLDINGS CORPORATION (to present) ^{*3}
June 2023	External Director of SAWAI GROUP HOLDINGS Co., Ltd. (to present)
June 2025	Outside Audit & Supervisory Board Member of MEDIPAL HOLDINGS CORPORATION (Scheduled) ^{*3}

*3. Scheduled to be elected as an Outside Audit & Supervisory Board Member of MEDIPAL HOLDINGS CORPORATION at the Ordinary General Meeting of Shareholders scheduled to be held on June 25, 2025, and to retire as an Advisor of MEDIPAL HOLDINGS CORPORATION.

[Name]	Miya Miyama
[Date of Birth]	June 13, 1972
[Brief biography]	
October 2002	Appointed Public Prosecutor (Public Prosecutor, Tokyo District Public Prosecutors Office)
July 2013	Head of Compliance Department of The Innovation Network Corporation of Japan
July 2016	Retired from position as Public Prosecutor
July 2016	Registered as an attorney at law of Japan Federation of Bar Associations (member of Dai-Ichi Tokyo Bar Association) CITY-YUWA PARTNERS (to present)
April 2018	Permanent Member of Dai-Ichi Tokyo Bar Association
April 2020	Vice Chair of Gender Equality Committee of Kanto Federation of Bar Associations
June 2021	Outside Director of Totetsu Kogyo Co., Ltd. (to present)

4. Board of Directors, Audit & Supervisory Board Members and Corporate Officers after June 25, 2025

Name	Title
Shin Ashida	Representative Director Chairman, President and CEO
Toru Ashida	Director, Senior Managing Executive Officer
Hiroyuki Sonoda, Ph.D.	Director, Senior Managing Executive Officer
Yoshio Hiyama, Ph.D.	Director, Managing Executive Officer
Andrea Spezzi, M.D., FFPM	Director, Managing Executive Officer
Takashi Suetsuna	Outside Director
Toshihide Yoda	Outside Director
Yuko Hayashi, Ph.D.	Outside Director
Yutaka Atomi, M.D., Ph.D.	Outside Director
Philippe Fauchet, OBE	Outside Director
Marc Dunoyer	Outside Director
Kazumasa Oizumi	Outside Audit & Supervisory Board Member (Active)
Masayuki Mitsuka	Outside Audit & Supervisory Board Member
Miya Miyama	Outside Audit & Supervisory Board Member
Toshihiro Ishikiriya	Senior Managing Executive Officer
Junichi Ando	Managing Executive Officer
Yoh Ito	Senior Executive Officer
Yutaka Honda	Senior Executive Officer
Takayo Egawa	Senior Executive Officer
Anne Bechet	Senior Executive Officer
Makoto Ashida	Executive Officer

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and belief – benefit all our stakeholders, including patients, partners, and employees. For more information, please visit.

<https://www.jcrpharm.co.jp/en/site/en/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###